<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585596</url>
  </required_header>
  <id_info>
    <org_study_id>YH23537-201</org_study_id>
    <nct_id>NCT02585596</nct_id>
  </id_info>
  <brief_title>A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.</brief_title>
  <official_title>A Double-blind, Randomized, Parallel, Placebo-active Controlled, Multi-center Phase II Clinical Trial to Investigate the Efficacy and Safety of YH23537 Following 12-week Oral Administration in Patients With Chronic Periodontal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and the safety of YH23537 in Korea patients
      with chronic periodontitis, in order to investigate the recommended therapeutic dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      at screening visit, at least existing 18 teeth,Mild/moderate/severe periodontitis patients
      diagnosed with chronic periodontitis according to the CDC / AAP (Center for Disease Control /
      American Academy for Periodontology) periodontitis classification (2012).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in probing pocket depth (PD)</measure>
    <time_frame>baseline, 4weeks, 8week, 12weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical attachment level (CAL)</measure>
    <time_frame>baseline, 4weeks, 8week, 12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bleeding on probing(BOP)</measure>
    <time_frame>baseline, 4weeks, 8week, 12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gingival recession(GR)</measure>
    <time_frame>baseline, 4weeks, 8week, 12weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>YH23537 1000mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH23537 500mg 1 tab, placebo 500mg 2tab twice a day (before morning,evening meal) during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH23537 2000mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH23537 500mg 2tab, placebo 500mg 1tab twice day (before morning,evening meal) during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH23537 3000mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH23537 500mg 3tab a day twice day (before morning,evening meal) during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH23537 3000mg/day loading 1000mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH23537 500mg 3tab twice a day (before morning,evening meal) during 4weeks and YH23537 500mg tab twice a day (before morning,evening meal) during 8weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>YH23537 500mg placebo 3tab twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH23537 1000mg/day</intervention_name>
    <description>YH23537 500mg 2 tab</description>
    <arm_group_label>YH23537 1000mg/day</arm_group_label>
    <arm_group_label>YH23537 3000mg/day loading 1000mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH23537 2000mg/day</intervention_name>
    <description>YH23537 500mg 4 tab</description>
    <arm_group_label>YH23537 2000mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH23537 3000mg/day</intervention_name>
    <description>YH23537 500mg 6 tab</description>
    <arm_group_label>YH23537 3000mg/day</arm_group_label>
    <arm_group_label>YH23537 3000mg/day loading 1000mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>YH23537 500mg tab placebo</description>
    <arm_group_label>YH23537 1000mg/day</arm_group_label>
    <arm_group_label>YH23537 2000mg/day</arm_group_label>
    <arm_group_label>YH23537 3000mg/day loading 1000mg/day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be 19 years of age or older

          -  Have at least 18 natural teeth

          -  have been diagnosed with chronic periodontitis

          -  have been diagnosed Mild/Moderate/Severe periodontitis with according to CDC / AAP
             periodontal classification (2012))

          -  Provide informed consent and willingness to cooperate with the study protocol

        Exclusion Criteria:

          -  Women of childbearing potential (WOCBP) who are unwilling or unable to use an
             acceptable method to avoid pregnancy for the entire study and for up to 4 weeks after
             the last dose of investigational product.

          -  Pregnant or lactating females

          -  Systemic diseases such as diabetes and hypertension

          -  Patients who take Anticoagulants or Antiplatelet Agents

          -  Continually use for phenytoin, calcium channel blocker, cyclosporin, coumarin,
             nonsteroidal anti-inflammatory drugs and aspirin use in the previous one month

          -  Patients who received periodontal treatment within the last 6 months

          -  Patients who have malignant tumor

          -  History of positive serologic evidence of current infectious liver disease including
             HbsAg, or anti-HCV.

          -  Patients with mental retardation and dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Incheol Rhyu, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Incheol Rhyu</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

